# Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer

> **NCT03316599** · PHASE1 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 26 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel
- **DRUG:** Ficlatuzumab

## Key facts

- **NCT ID:** NCT03316599
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-17
- **Primary completion:** 2020-10-10
- **Final completion:** 2021-07-29
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2021-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03316599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03316599, "Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03316599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*